Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
Background Given the association between nonalcoholic fatty liver disease and metabolic risks, a new term, metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed. We aimed to explore the association between MASLD and all-cause, cause-specific mortalities. Methods We inclu...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2025-01-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://e-dmj.org/upload/pdf/dmj-2024-0042.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527852659376128 |
|---|---|
| author | Rosa Oh Seohyun Kim So Hyun Cho Jiyoon Kim You-Bin Lee Sang-Man Jin Kyu Yeon Hur Gyuri Kim Jae Hyeon Kim |
| author_facet | Rosa Oh Seohyun Kim So Hyun Cho Jiyoon Kim You-Bin Lee Sang-Man Jin Kyu Yeon Hur Gyuri Kim Jae Hyeon Kim |
| author_sort | Rosa Oh |
| collection | DOAJ |
| description | Background Given the association between nonalcoholic fatty liver disease and metabolic risks, a new term, metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed. We aimed to explore the association between MASLD and all-cause, cause-specific mortalities. Methods We included individuals with steatotic liver disease (SLD) from the Korean National Health Insurance Service. Moreover, SLD was defined as a fatty liver index ≥30. Furthermore, MASLD, metabolic alcohol-associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction (MD) were categorized based on alcohol consumption and MD. We also analyzed all-cause, liver-, cancer-, hepatocellular carcinoma (HCC)- and cardiovascular (CV)-related mortalities. Results This retrospective nationwide cohort study included 1,298,993 individuals aged 40 to 79 years for a mean follow-up duration of 9.04 years. The prevalence of MASLD, MetALD, and ALD with MD was 33.11%, 3.93%, and 1.00%, respectively. Relative to the “no SLD” group, multivariable analysis identified that MASLD (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.26 to 1.31), MetALD (aHR, 1.38; 95% CI, 1.32 to 1.44), and ALD with MD group (aHR, 1.80; 95% CI, 1.68 to 1.93) have a significantly higher risk of all-cause mortality. Furthermore, MASLD, MetALD, ALD with MD groups showed higher liver-, cancer-, and HCC-related mortality than “no SLD” group. While all-cause specific mortalities increase from MASLD to MetALD to ALD with MD, the MetALD group shows a lower risk of CV-related mortality compared to MASLD. However, ALD with MD group still have a higher risk of CV-related mortality compared to MASLD. Conclusion SLD is associated with an increased risk of all-cause, liver-, cancer-, HCC-, and CV-related mortalities. |
| format | Article |
| id | doaj-art-c12737392d214a8ba8545d3d5883d073 |
| institution | Kabale University |
| issn | 2233-6079 2233-6087 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj-art-c12737392d214a8ba8545d3d5883d0732025-01-15T07:46:19ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872025-01-01491809110.4093/dmj.2024.00422873Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific MortalityRosa Oh0Seohyun Kim1So Hyun Cho2Jiyoon Kim3You-Bin Lee4Sang-Man Jin5Kyu Yeon Hur6Gyuri Kim7Jae Hyeon Kim8 Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaBackground Given the association between nonalcoholic fatty liver disease and metabolic risks, a new term, metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed. We aimed to explore the association between MASLD and all-cause, cause-specific mortalities. Methods We included individuals with steatotic liver disease (SLD) from the Korean National Health Insurance Service. Moreover, SLD was defined as a fatty liver index ≥30. Furthermore, MASLD, metabolic alcohol-associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction (MD) were categorized based on alcohol consumption and MD. We also analyzed all-cause, liver-, cancer-, hepatocellular carcinoma (HCC)- and cardiovascular (CV)-related mortalities. Results This retrospective nationwide cohort study included 1,298,993 individuals aged 40 to 79 years for a mean follow-up duration of 9.04 years. The prevalence of MASLD, MetALD, and ALD with MD was 33.11%, 3.93%, and 1.00%, respectively. Relative to the “no SLD” group, multivariable analysis identified that MASLD (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.26 to 1.31), MetALD (aHR, 1.38; 95% CI, 1.32 to 1.44), and ALD with MD group (aHR, 1.80; 95% CI, 1.68 to 1.93) have a significantly higher risk of all-cause mortality. Furthermore, MASLD, MetALD, ALD with MD groups showed higher liver-, cancer-, and HCC-related mortality than “no SLD” group. While all-cause specific mortalities increase from MASLD to MetALD to ALD with MD, the MetALD group shows a lower risk of CV-related mortality compared to MASLD. However, ALD with MD group still have a higher risk of CV-related mortality compared to MASLD. Conclusion SLD is associated with an increased risk of all-cause, liver-, cancer-, HCC-, and CV-related mortalities.http://e-dmj.org/upload/pdf/dmj-2024-0042.pdffatty livermetabolic syndromemortality |
| spellingShingle | Rosa Oh Seohyun Kim So Hyun Cho Jiyoon Kim You-Bin Lee Sang-Man Jin Kyu Yeon Hur Gyuri Kim Jae Hyeon Kim Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality Diabetes & Metabolism Journal fatty liver metabolic syndrome mortality |
| title | Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality |
| title_full | Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality |
| title_fullStr | Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality |
| title_full_unstemmed | Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality |
| title_short | Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality |
| title_sort | metabolic dysfunction associated steatotic liver disease and all cause and cause specific mortality |
| topic | fatty liver metabolic syndrome mortality |
| url | http://e-dmj.org/upload/pdf/dmj-2024-0042.pdf |
| work_keys_str_mv | AT rosaoh metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT seohyunkim metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT sohyuncho metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT jiyoonkim metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT youbinlee metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT sangmanjin metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT kyuyeonhur metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT gyurikim metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality AT jaehyeonkim metabolicdysfunctionassociatedsteatoticliverdiseaseandallcauseandcausespecificmortality |